Patent US2012458A successfully refreshed from Google Patents.
Patent US4677121A successfully refreshed from Google Patents.
US4677121A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inhibiting muscle protein degradation
Assignee: Johns Hopkins University
•
Filing: 1985-10-31
•
Granted: 1987-06-30
•
Expires: 2005-10-31
Abstract
Abstract Muscle protein breakdown or degradation may be reduced or inhibited in mammals, particularly humans recovering from surgery or suffering from a muscle wasting disorder, by administering daily doses of alpha-ketoisocaproic acid (ketoleucine) or an appropriate salt of the acid. Seventy millimoles per day of sodium alpha-ketoisocaproate administered for five days after major abdominal surgery was found to significantly reduce urinary 3-methylhistidine/creatinine, which is a measure of muscle protein breakdown, and thereby to improve nitrogen balance.
Inventors
- 👤 Mackenzie Walser
- 👤 Daniel G. Sapir
- 👤 Peter M. Stewart
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 20:04
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
35 words
A method of reducing muscle protein degradation in patients suffering from such degradation comprising administering to said patient an effective amount of a composition consisting essentially of alpha-ketoisocaproic acid or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
35 words
A method of reducing muscle protein degradation in patients suffering from such degradation comprising administering to said patient an effective amount of a composition consisting essentially of alpha-ketoisocaproic acid or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
13 words
A method according to claim 1 wherein the patient is recovering from surgery.
Claim 4
Dependent Claim
20 words
A method according to claim 2 wherein sodium alpha-ketoisocaproate is administered in an amount of about 70 millimoles per day.
Claim 5
Dependent Claim
16 words
A method according to claim 1 wherein the patient is suffering from a muscle wasting disorder.
Claim 6
Dependent Claim
15 words
A method according to claim 1 wherein the salt of alpha-ketoisocaproic acid is sodium alpha-ketoisocaproate.
Claim 7
Dependent Claim
20 words
A method according to claim 1 wherein said composition is in the form of a solution which is administered intravenously.
Claim 8
Dependent Claim
32 words
A method according to claim 1 wherein the patient is suffering from a condition or disease where there is a disparity between the rates of muscle protein synthesis and muscle protein degradation.
Claim 9
Dependent Claim
16 words
A method according to claim 7 wherein the patient is suffering from accelerated muscle protein degradation.
References Cited (Backward Citations)
US4100161A
Cited
US4100160A
Cited
US4100293A
Cited
US4228099A
Cited
US4320146A
Cited
US4296127A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-29 | 1990-12-29 | 1991-06-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-29 | 1994-12-29 | 1995-06-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-29 | 1998-12-29 | 1999-06-30 | $7700.00 | Window Closed / Lapsed |